Susan F Slovin

Susan F Slovin

UNVERIFIED PROFILE

Are you Susan F Slovin?   Register this Author

Register author
Susan F Slovin

Susan F Slovin

Publications by authors named "Susan F Slovin"

Are you Susan F Slovin?   Register this Author

80Publications

1446Reads

20Profile Views

Malignant priapism in metastatic prostate cancer: A late event occurring early.

Urol Case Rep 2018 Jul 31;19:1-3. Epub 2018 Mar 31.

Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eucr.2018.03.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991306PMC
July 2018

The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies.

Authors:
Susan F Slovin

Biomark Med 2017 Dec 30;11(12):1149-1159. Epub 2017 Nov 30.

Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/bmm-2017-0138DOI Listing
December 2017

Sipuleucel-T: When and for Whom to Recommend It.

Authors:
Susan F Slovin

Oncology (Williston Park) 2017 12;31(12):900-1, 910-2

View Article

Download full-text PDF

Source
December 2017

Immune Therapy for Prostate Cancer.

Cancer J 2016 Sep/Oct;22(5):334-341

From the Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000223DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117426PMC
August 2017

Radium-223 and concomitant therapies: prospects and prudence.

Transl Androl Urol 2016 Dec;5(6):968-970

Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tau.2016.11.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5182218PMC
December 2016

Immunotherapy for prostate cancer: is prostate an immune responsive tumor?

Authors:
Susan F Slovin

Curr Opin Urol 2016 11;26(6):529-34

Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000334DOI Listing
November 2016

Immunotherapy in metastatic prostate cancer.

Authors:
Susan F Slovin

Indian J Urol 2016 Oct-Dec;32(4):271-276

Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0970-1591.191240DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054656PMC
November 2016

Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design.

Authors:
Susan F Slovin

Immunotargets Ther 2014 16;3:1-8. Epub 2013 Dec 16.

Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/ITT.S30821DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918229PMC
July 2016

A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.

J Clin Oncol 2016 06 4;34(16):1913-20. Epub 2016 Apr 4.

Rana R. McKay, Lillian Werner, Christopher J. Sweeney, Philip W. Kantoff, and Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston; Robert W. Ross, Bluebird Bio, Cambridge, MA; Amado J. Zurita and Hai T. Tran, MD Anderson Cancer Center, Houston, TX; Justine Y. Bruce, University of Wisconsin Carbone Cancer Center, Madison, WI; Michael A. Carducci, Johns Hopkins University; Arif Hussain, Greenebaum Cancer Center, Baltimore, MD; Mark N. Stein, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Elisabeth I. Heath, Karmanos Cancer Institute, Detroit, MI; and Philip W. Kantoff and Susan F. Slovin, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.3154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321094PMC
June 2016

Biomarkers for immunotherapy in genitourinary malignancies.

Authors:
Susan F Slovin

Urol Oncol 2016 Apr 16;34(4):205-13. Epub 2015 Mar 16.

Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2015.02.007DOI Listing
April 2016

Immunotherapy for genitourinary malignancies in the here and now!

Authors:
Susan F Slovin

Urol Oncol 2016 Apr 17;34(4):169-70. Epub 2015 Dec 17.

Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urology Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2015.11.008DOI Listing
April 2016

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol 2016 Apr 22;34(12):1402-18. Epub 2016 Feb 22.

Howard I. Scher, Michael J. Morris, Dana E. Rathkopf, and Susan F. Slovin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; David Nanus, NewYork Presbyterian Weill Cornell Medical Center; Lawrence W. Schwartz, NewYork Presbyterian Columbia University Medical Center, New York, NY; Walter M. Stadler, University of Chicago Medicine, Chicago, IL; Celestina Higano and Peter S. Nelson, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC; Emmanual S. Antonarakis and Michael A. Carducci, Johns Hopkins University School of Medicine, Baltimore, MD; Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Paul G. Corn and Christopher Logothetis, MD Anderson Cancer Center, Houston, TX; Robert Dreicer, University of Virginia School of Medicine, Charlottesville, VA; Daniel J. George, Susan Halabi, and Andrew J. Armstrong, Duke University and Duke Cancer Institute, Durham, NC; Elisabeth I. Heath, Wayne State University Karmanos Cancer Institute, Detroit; and Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Wm. Kevin Kelly, Sidney Kimmel School of Medicine at Thomas Jefferson University, Philadelphia, PA; Glenn Liu and George Wilding, University of Wisconsin Carbone Cancer Center, Madison, WI; Mark N. Stein, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ; Charles S. Ryan and Eric J. Small, University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Oliver Sartor, Tulane School of Medicine, New Orleans, LA; Matthew Raymond Smith, Massachusetts General Hospital Cancer Center and Harvard Medical School; Mary-Ellen Taplin and Philip W. Kantoff, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.2702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872347PMC
April 2016

Immunotherapeutic approaches in prostate cancer: combinations and clinical integration.

Authors:
Susan F Slovin

Am Soc Clin Oncol Educ Book 2015 :e275-83

From the Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e275DOI Listing
February 2016

Metabolism and pharmacokinetics of radium-223 in prostate cancer.

Expert Opin Drug Metab Toxicol 2015 May 4;11(5):843-9. Epub 2015 Mar 4.

Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, Genitourinary Oncology Service , 1275 York Avenue, New York, NY 10065 , USA +1 646 422 4470 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425255.2015.1021332DOI Listing
May 2015

American Cancer Society prostate cancer survivorship care guidelines.

CA Cancer J Clin 2014 Jul-Aug;64(4):225-49. Epub 2014 Jun 10.

Assistant Professor of Urology, Department of Urology, University of Michigan, Research Investigator, HSR&D Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21234DOI Listing
September 2014

Organoid cultures derived from patients with advanced prostate cancer.

Cell 2014 Sep 4;159(1):176-187. Epub 2014 Sep 4.

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2014.08.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237931PMC
September 2014

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.

Sci Transl Med 2014 Apr;6(230):230ra45

Department of Pathology, Johns Hopkins University, Baltimore, MD 21205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3008002DOI Listing
April 2014

Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs.

Authors:
Susan F Slovin

Immunotherapy 2013 Dec;5(12):1347-55

Genitourinary Oncology Service, Sidney Kimmel Center for Prostate & Urologic Cancers, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.13.140DOI Listing
December 2013

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

J Clin Oncol 2013 Oct 3;31(28):3525-30. Epub 2013 Sep 3.

Dana E. Rathkopf, Michael J. Morris, Josef J. Fox, Daniel C. Danila, Susan F. Slovin, Mithat Gönen, Martin Fleisher, Steven M. Larson, Charles L. Sawyers, and Howard I. Scher, Memorial Sloan-Kettering Cancer Center; Dana E. Rathkopf, Michael J. Morris, Josef J. Fox, Daniel C. Danila, Susan F. Slovin, Steven M. Larson, and Howard I. Scher, Weill Cornell Medical College, New York, NY; Jeffrey H. Hager, Peter J. Rix, Edna Chow Maneval, and Isan Chen, Aragon Pharmaceuticals, San Diego, CA; and Charles L. Sawyers, Howard Hughes Medical Institute, Chevy Chase, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.1684DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782148PMC
October 2013

Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.

Cancer 2013 Sep 13;119(17):3186-94. Epub 2013 Jun 13.

Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775970PMC
September 2013

Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future?

Semin Oncol 2013 Jun;40(3):347-60

Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2013.04.009DOI Listing
June 2013

A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.

Vaccine 2013 Jan 13;31(6):943-9. Epub 2012 Dec 13.

Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2012.11.096DOI Listing
January 2013

Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.

Cancer Chemother Pharmacol 2012 Mar 22;69(3):763-71. Epub 2011 Oct 22.

Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, CRB1-1M59, 1650 Orleans Street, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-011-1759-9
Publisher Site
http://dx.doi.org/10.1007/s00280-011-1759-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586214PMC
March 2012

Are we trumping bone disease in prostate cancer?

Authors:
Susan F Slovin

Oncology (Williston Park) 2011 Dec;25(14):1390, 1393

Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
December 2011

Enhancing Immunogenicity of Cancer Vaccines: QS-21 as an Immune Adjuvant.

Curr Drug ther 2011 Aug;6(3):207-212

Associate Attending Physician, Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, NY, and Associate Professor of Medicine, Weill-Cornell Medical College, NY.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248601PMC
August 2011

Seeking informed consent to Phase I cancer clinical trials: identifying oncologists' communication strategies.

Psychooncology 2011 Apr 7;20(4):361-8. Epub 2010 Apr 7.

Department of Social and Behavioral Health, Virginia Commonwealth University School of Medicine, Richmond, VA 23298-0581, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pon.1748DOI Listing
April 2011

Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas.

Mod Pathol 2010 Aug 21;23(8):1104-12. Epub 2010 May 21.

Howard Hughes Medical Institute, Immunology Program, Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2010.95DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2976590PMC
August 2010

A clinical trials outcome paradox: should survival prevail in the absence of clinical benefit?

Authors:
Susan F Slovin

Immunotherapy 2010 Mar;2(2):155-8

Genitourinary Oncology Service, Sidney Kimmel Center for Prostate & Urologic Cancers, Memorial Sloan-Kettering Cancer Center, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.10.5DOI Listing
March 2010

Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer.

Clin Genitourin Cancer 2009 Oct;7(3):E77-82

Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S155876731170035
Publisher Site
http://dx.doi.org/10.3816/CGC.2009.n.028DOI Listing
October 2009

Cognitive effects of hormonal therapy in older adults.

Semin Oncol 2008 Dec;35(6):569-81

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2008.08.002DOI Listing
December 2008

Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage.

Cancer Res 2008 Aug;68(15):6054-8

Department of Surgery, Urology Service, Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-08-0869DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2918370PMC
August 2008

Scrotal and penile papules and plaques as the initial manifestation of a cutaneous metastasis of adenocarcinoma of the prostate: case report and review of the literature.

J Cutan Pathol 2008 Jul 14;35(7):681-4. Epub 2008 Jan 14.

Department of Medicine, Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0560.2007.00873.xDOI Listing
July 2008

Pitfalls or promise in prostate cancer immunotherapy-which is winning?

Authors:
Susan F Slovin

Cancer J 2008 Jan-Feb;14(1):26-34

Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancer, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e318161bffaDOI Listing
May 2008

Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.

J Clin Oncol 2008 May 24;26(13):2147-54. Epub 2008 Mar 24.

Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.15.0532DOI Listing
May 2008

Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory?

Authors:
Susan F Slovin

Expert Rev Anticancer Ther 2008 Mar;8(3):465-74

Sidney Kimmel Center for Prostate & Urologic Cancers, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.8.3.465DOI Listing
March 2008

A polyvalent vaccine for high-risk prostate patients: "are more antigens better?".

Cancer Immunol Immunother 2007 Dec 10;56(12):1921-30. Epub 2007 Jul 10.

Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-007-0335-yDOI Listing
December 2007

Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome.

Authors:
Susan F Slovin

Clin Adv Hematol Oncol 2007 Dec;5(12):972-80

Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
December 2007

Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.

Authors:
Susan F Slovin

Nat Clin Pract Oncol 2007 Sep;4(9):551-4

Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncponc0910DOI Listing
September 2007

Emerging role of immunotherapy in the management of prostate cancer.

Authors:
Susan F Slovin

Oncology (Williston Park) 2007 Mar;21(3):326-33; discussion 334, 338, 346-8

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
March 2007

Immunologic targeting: how to channel a minimal response for maximal outcome.

Authors:
Susan F Slovin

Curr Opin Urol 2006 May;16(3):179-85

Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.mou.0000193396.00340.e5DOI Listing
May 2006

Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing?

Authors:
Susan F Slovin

Nat Clin Pract Urol 2006 Mar;3(3):138-44

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncpuro0435DOI Listing
March 2006

Violaceous exanthem as a manifestation of metastatic prostate cancer in skin.

Urology 2006 Feb;67(2):420

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2005.08.033DOI Listing
February 2006

Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy.

Clin Cancer Res 2005 Dec;11(24 Pt 1):8669-73

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-1668DOI Listing
December 2005

Fifth International Prostate Cancer Congress. 1-3 July 2005, Rio Grande, Puerto Rico.

Authors:
Susan F Slovin

IDrugs 2005 Sep;8(9):710-2

Memorial Sloan-Kettering Cancer Center, Genitourinary Oncology Service, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
September 2005

Second-line chemotherapy for prostate cancer: patient characteristics and survival.

Clin Prostate Cancer 2005 Sep;4(2):86-90

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
September 2005

Prostate-specific membrane antigen vaccines: naked DNA and protein approaches.

Authors:
Susan F Slovin

Clin Prostate Cancer 2005 Sep;4(2):118-23

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center New York, NY 10021, USA.

View Article

Download full-text PDF

Source
September 2005

Carbohydrate vaccines as immunotherapy for cancer.

Immunol Cell Biol 2005 Aug;83(4):418-28

Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1440-1711.2005.01350.xDOI Listing
August 2005

Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen.

Authors:
Susan F Slovin

Expert Opin Ther Targets 2005 Jun;9(3):561-70

Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.9.3.561 DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1855285PMC
June 2005

Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer.

Appl Immunohistochem Mol Morphol 2005 Mar;13(1):6-13

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
March 2005

Cancer immunotherapeutics meeting.

Authors:
Susan F Slovin

Expert Opin Investig Drugs 2004 Dec;13(12):1645-50

Memorial Sloan-Kettering Cancer Center, Genitourinary Oncology Service, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.13.12.1645DOI Listing
December 2004

Dendritic cell vaccines--hopeful or hopeless?

Authors:
Susan F Slovin

Cancer Invest 2003 ;21(6):969-70

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1081/cnv-120025101DOI Listing
February 2004

Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer.

Urology 2003 Dec;62 Suppl 1:102-18

Genitourinary Oncology Program, Greenebaum Cancer Institute, University of Maryland, Baltimore, Maryland 21201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2003.10.027DOI Listing
December 2003

DNA vaccines: an active immunization strategy for prostate cancer.

Semin Oncol 2003 Oct;30(5):659-66

Clinical Immunology Services, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
October 2003

Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.

Clin Cancer Res 2002 Mar;8(3):679-83

Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
March 2002

HER-2 profiling and targeting in prostate carcinoma.

Cancer 2002 Feb;94(4):980-6

Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
February 2002

A Fully Synthetic Globo H Carbohydrate Vaccine Induces a Focused Humoral Response in Prostate Cancer Patients: A Proof of Principle.

Angew Chem Int Ed Engl 1999 Feb;38(4):563-566

Laboratory for Bioorganic Chemistry, Sloan-Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10021 (USA), Fax: (+1) 212-772-8691.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/(SICI)1521-3773(19990215)38:4<563::AID-ANIE563>3.0.CO;2-3DOI Listing
February 1999